Hebei Changshan Biochemical Pharmaceutical Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Hebei Changshan Biochemical Pharmaceutical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30
Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hebei Changshan Biochemical Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 1,055 | -845 | 142 | 307 | N/A |
| 6/30/2024 | 1,158 | -1,131 | 210 | 400 | N/A |
| 3/31/2024 | 1,203 | -1,306 | 56 | 247 | N/A |
| 12/31/2023 | 1,410 | -1,240 | -206 | 34 | N/A |
| 9/30/2023 | 1,682 | -438 | -245 | 63 | N/A |
| 6/30/2023 | 2,010 | -203 | -222 | 120 | N/A |
| 3/31/2023 | 2,264 | -8 | -321 | 62 | N/A |
| 1/1/2023 | 2,336 | 18 | -428 | 3 | N/A |
| 9/30/2022 | 2,603 | 94 | -490 | -39 | N/A |
| 6/30/2022 | 2,697 | 141 | -827 | -398 | N/A |
| 3/31/2022 | 2,832 | 195 | -657 | -230 | N/A |
| 1/1/2022 | 2,968 | 234 | -305 | 3 | N/A |
| 9/30/2021 | 2,885 | 255 | -184 | 77 | N/A |
| 6/30/2021 | 2,771 | 279 | 106 | 352 | N/A |
| 3/31/2021 | 2,676 | 273 | -7 | 198 | N/A |
| 12/31/2020 | 2,364 | 253 | -383 | -184 | N/A |
| 9/30/2020 | 2,280 | 236 | -424 | -266 | N/A |
| 6/30/2020 | 2,178 | 233 | -370 | -233 | N/A |
| 3/31/2020 | 2,011 | 217 | -377 | -236 | N/A |
| 12/31/2019 | 2,071 | 225 | -222 | -58 | N/A |
| 9/30/2019 | 1,930 | 173 | -132 | 60 | N/A |
| 6/30/2019 | 1,841 | 157 | -199 | 43 | N/A |
| 3/31/2019 | 1,783 | 151 | -2 | 248 | N/A |
| 12/31/2018 | 1,653 | 140 | 58 | 293 | N/A |
| 9/30/2018 | 1,691 | 225 | 117 | 327 | N/A |
| 6/30/2018 | 1,621 | 219 | N/A | 287 | N/A |
| 3/31/2018 | 1,493 | 199 | N/A | 151 | N/A |
| 12/31/2017 | 1,420 | 197 | N/A | 162 | N/A |
| 9/30/2017 | 1,189 | 208 | N/A | -40 | N/A |
| 6/30/2017 | 1,119 | 190 | N/A | -52 | N/A |
| 3/31/2017 | 1,143 | 190 | N/A | 110 | N/A |
| 12/31/2016 | 1,118 | 175 | N/A | 172 | N/A |
| 9/30/2016 | 1,082 | 171 | N/A | 174 | N/A |
| 6/30/2016 | 1,008 | 165 | N/A | 206 | N/A |
| 3/31/2016 | 949 | 161 | N/A | 57 | N/A |
| 12/31/2015 | 916 | 156 | N/A | -38 | N/A |
| 9/30/2015 | 895 | 147 | N/A | 4 | N/A |
| 6/30/2015 | 877 | 139 | N/A | 14 | N/A |
| 3/31/2015 | 831 | 135 | N/A | -100 | N/A |
| 12/31/2014 | 811 | 134 | N/A | -85 | N/A |
| 9/30/2014 | 716 | 119 | N/A | -177 | N/A |
| 6/30/2014 | 693 | 116 | N/A | -254 | N/A |
| 3/31/2014 | 723 | 116 | N/A | -9 | N/A |
| 12/31/2013 | 705 | 115 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 300255's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 300255's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 300255's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 300255's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 300255's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 300255's Return on Equity is forecast to be high in 3 years time